Cancer Institute A national cancer institute
designated cancer center

Michael Link

Publication Details

  • Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood ANNALS OF ONCOLOGY Hutchison, R. E., Banki, K., Shuster, J. J., Barrett, D., Dieck, C., Berard, C. W., Murphy, S. B., Link, M. P., Pick, T. E., Laver, J., Schwenn, M., Mathew, P., Morris, S. W. 1997; 8: 37-42


    Anaplastic lymphoma kinase (ALK) is a tyrosine kinase inappropriately expressed in lymphoid tissue involved by CD30+ anaplastic large-cell lymphoma (ALCL) with the translocation t(2;5)(p23;q35)(, which juxtaposes the nucleophosmin gene (NPM) with that encoding ALK, resulting in a hybrid (NPM-ALK) message.A polyclonal antibody against residues of the kinase portion of NPM-ALK (designated anti-ALK 11) was tested for clinical utility in paraffin sections of 44 cases of pediatric large-cell lymphoma (LCL) and 17 additional lymphoma cases, by streptavidin-biotin-alkaline phosphatase method.Nineteen of 20 CD30+ cases (the majority exhibiting anaplastic morphology) labeled with anti-ALK 11, and 5/28 CD30- cases were also ALK+ (3 T cells, 1 null cell, and 1 B cell). Sixteen of 17 B-cell pediatric LCLs were negative, as were 6/6 cases of Hodgkin's disease and 7/7 cases of adult B-cell lymphoma. In pediatric LCLs with adequate follow-up (24/44 ALK+), there was no significant association between ALK expression and two-year event-free survival, similar to the finding reported previously for CD30 expression in these cases.We conclude that the majority of pediatric CD30+ ALCLs show ALK overexpression, consistent with the presence of the t(2;5)-encoded NPM-ALK fusion, but that the clinical significance of this entity remains unproven.

    View details for Web of Science ID A1997XB82400008

    View details for PubMedID 9187427

Stanford Medicine Resources:

Footer Links: